Dexcom Stock News

Tech stocks got off to a positive start Wednesday morning. The Nasdaq traded up about 1.3%, the S&P 500 was up 1.04% and the Dow traded 0.7% higher shortly after the opening bell.

Both companies still have miles of growth left ahead.

Dexcom (DXCM) said people with diabetes who are under 18 years of age and require ongoing use of insulin or insulin pump therapy are eligible for public coverage of Dexcom G6 CGM…

Analysts have provided the following ratings for DexCom (NASDAQ: DXCM ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 2 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 These 5 analysts have an average price target of $559.6 versus the current price of DexCom at $424.72, implying upside. Below is a summary of how these 5 analysts rated DexCom over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater … Full story available on Benzinga.com

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.

DexCom One and G7 can prove to be a solid growth catalysts for this leading CGM player. DexCom has also secured FDA approval for two key software solutions, which can further help the company integrat

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #DXCM--Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time

naphtalina/iStock via Getty Images Following a three-day selloff, DexCom (DXCM +2.9%) shares are trading higher after Wells Fargo upgraded the maker of continuous glucose monitoring

DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

DexCom (DXCM) posts solid fourth-quarter and full-year 2021 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.

Kevin Sayer, the chief executive officer of Dexcom, appeared on Monday's episode of "Mad Money," discussing efforts to increase awareness of its continuous glucose monitoring devices, including its ne

DexCom <> expects preliminary, unaudited revenue for Q4 to be ~$698M, an increase of 23% Y/Y (consensus of $696.01M).U.S

SAN DIEGO--(BUSINESS WIRE)--Dexcom to Present at 40th Annual J.P. Morgan Healthcare Conference